Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): A population control study

Rojana-udomsart, Arada; Bundell, Christine; James, Ian; Castley, Alison; Martínez, Patricia; Christiansen, Frank; Hollingsworth, Peter; Mastaglia, Frank

doi:10.1016/j.jneuroim.2012.04.007

Cited by 25 publications

(15 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies for Australian general populations so far have been restricted to AAbs associated with a few select diseases, e.g., systemic lupus erythematosus, 27 multiple sclerosis, 24 and myositis. 28 In our study at least one AAb was detected in 51.5% of individuals. An even higher number of individuals with one or more AAbs had been reported in 1972 for the Busselton cohort.…”

Section: Discussionsupporting

confidence: 54%

“…Previous studies have either investigated a single AAb only or they have been cross-sectional but focused on estimating the prevalence of AAbs relevant to certain diseases in control populations. 24,27,28 So far, there is only one other report on the prevalence of serum AAbs in the general Australian population, published in 1972, 26 and more contemporary studies are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Low level autoantibodies can be frequently detected in the general Australian population

et al. 2016

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 54%

Section: Introductionmentioning

confidence: 99%

Low level autoantibodies can be frequently detected in the general Australian population

et al. 2016

Self Cite

View full text Add to dashboard Cite

“…Inclusion body myositis has been traditionally viewed as a degenerative myopathy with secondary inflammation, rather than a primary autoimmune disease. Supporting this hypothesis, until recently, only a small proportion (17-43%) of IBM patients were routinely found to be autoantibody positive, with the majority of these cases involving MAAs as opposed to MSAs [105]. However, in 2011, two groups simultaneously described novel autoantibodies in IBM, with Salajegheh et al reporting a 43-kDa target and Pluk et al reporting autoantibodies targeting a 44-kDa protein [106,107].…”

Section: Anti-cn1amentioning

confidence: 99%

Myositis‐specific autoantibodies: an important tool to support diagnosis of myositis

2015

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies are characterized by muscle weakness, skin disease and internal organ involvement. Autoimmunity is known to have a role in myositis pathogenesis, and myositis‐specific autoantibodies, targeting important intracellular proteins, are regarded as key biomarkers aiding in the diagnosis of patients. In recent years, a number of novel myositis autoantibodies including anti‐TIF1, anti‐NXP2, anti‐MDA5, anti‐SAE, anti‐HMGCR and anti‐cN1A have been identified in both adult and juvenile patients. These autoantibodies correlate with distinct clinical manifestations and importantly are found in inclusion body, statin‐induced, clinically amyopathic and juvenile groups of myositis patients, previously believed to be mainly autoantibody negative. In this review, we will describe the main myositis‐specific and myositis‐associated autoantibodies and their frequencies and clinical associations across different ages and ethnic groups. We will also discuss preliminary studies investigating correlations between specific myositis autoantibody titres and clinical markers of disease course, collectively demonstrating the utility of myositis autoantibodies as both diagnostic and prognostic markers of disease.

show abstract

“…However, anti-cN-1A antibodies are also detectable in up to 20% of patients with Sjögren syndrome and systemic lupus erythematosus in the absence of a myopathy, and have also been found in patients with DM or PM as well as healthy volunteers [89,90]. There is also an association between IBM and certain autoimmune conditions, including Sjögren syndrome, sarcoidosis, and lymphoproliferative disorders (chronic lymphocytic leukemia/lymphocytosis) [63,65], and less specific autoimmune antibodies, including anti-Ro, anti-La, antinuclear antibody, anti-rheumatoid factor, anti-Smith, and anti-RNP antibodies, have also been reported in up to 20% of patients with IBM [60,91,92].…”

Section: Laboratory Features Including Myositis Antibodiesmentioning

confidence: 99%

Autoimmune Myopathies: Updates on Evaluation and Treatment

2018

View full text Add to dashboard Cite

The major forms of autoimmune myopathies include dermatomyositis (DM), polymyositis (PM), myositis associated with antisynthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM). While each of these conditions has unique clinical and histopathological features, they all share an immune-mediated component. These conditions can occur in isolation or can be associated with systemic malignancies or connective tissue disorders (overlap syndromes). As more has been learned about these conditions, it has become clear that traditional classification schemes do not adequately group patients according to shared clinical features and prognosis. Newer classifications are now utilizing myositis-specific autoantibodies which correlate with clinical and histopathological phenotypes and risk of malignancy, and help in offering prognostic information with regard to treatment response. Based on observational data and expert opinion, corticosteroids are considered first-line therapy for DM, PM, ASS, and IMNM, although intravenous immunoglobulin (IVIG) is increasingly being used as initial therapy in IMNM related to statin use. Second-line agents are often required, but further prospective investigation is required regarding the optimal choice and timing of these agents.

show abstract

Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): A population control study

Cited by 25 publications

References 35 publications

Low level autoantibodies can be frequently detected in the general Australian population

Low level autoantibodies can be frequently detected in the general Australian population

Myositis‐specific autoantibodies: an important tool to support diagnosis of myositis

Autoimmune Myopathies: Updates on Evaluation and Treatment

Contact Info

Product

Resources

About